萬馬股份(002276.SZ):與萬華化學共同投資萬馬萬華上下游一體化項目
格隆匯5月22日丨萬馬股份(002276.SZ)發佈公吿,2022年5月21日,公司第五屆董事會第二十七次會議審議通過《關於與萬華化學共同投資萬馬萬華上下游一體化項目的議案》。為實施萬馬萬華上下游一體化項目,萬馬高分子集團、萬華化學(福建)與福州江陰港城經濟區管理委員會共同簽訂《福清萬馬萬華上下游一體化項目投資合同》。根據本投資合同約定,萬馬高分子集團、萬華化學(福建)將合資成立福建萬驊高分子材料有限公司(暫定名,具體以工商最終核定為準),以實施本上下游一體化項目,其中萬馬高分子集團股權佔比60%,萬華化學(福建)股權佔比40%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.